Propofol can reduce the expression of PCNA, CD34, and PATK proteins in patients, thereby increasing the activity and content of transforming growth factor TGF-β1 by 12% and 20%, respectively, thereby inhibiting the proliferation rate of liver cancer cells by 10% through the Smad2 signaling pathway. This evidence concerns the gene TGFB1 and liver cancer.